Amorfix presents vCJD blood test results from its commercial high-throughput platform at the TSE conference in Berlin



    TSX Venture: AMF

    TORONTO, June 27 /CNW/ - Amorfix Life Sciences (TSX-V:AMF), a company
focused on diagnostics and treatments for brain wasting diseases, today
announced that Dr. Neil Cashman, Chief Scientific Officer of Amorfix,
presented an overview of the Company's proprietary Epitope Protection (EP)
technology for the in vitro detection of variant Creutzfeldt-Jacob Disease
(vCJD) at the Transmissible Spongiform Encephalopathies (TSE) Conference held
earlier today in Berlin, Germany. The presentation entitled, "Detection of
vCJD prions in blood using epitope protection" highlighted the sensitivity and
specificity of the EP-vCJD(TM) high-throughput diagnostic test for screening
blood donations.
    "The blood transfusion services in Europe need a screening test to
protect the blood supply from transmission of vCJD. This conference provided
an opportunity to showcase and increase the awareness of our proprietary
EP-vCJD(TM) diagnostic test with the European blood agencies and regulatory
authorities," said Dr. George Adams, CEO of Amorfix Life Sciences. "Our test
kits are now available for research purposes which allows for its use for
prevalence studies to assess the number of people that have vCJD and the risk
of blood transfusion in regions where contaminated beef was consumed."

    About Amorfix

    Amorfix is an emerging theranostics company focused on the diagnosis and
treatment of brain-wasting diseases, where aggregated misfolded proteins
(AMPs) are prevalent. These include "prions", the infectious agents of the
Transmissible Spongiform Encephalopathies (TSE), such as BSE and variant CJD,
as well as degenerative diseases such as Alzheimer's Disease, ALS and
Parkinson's Disease. Amorfix is focused on discovering and commercializing
technologies to become the world leader on AMP diseases. The company will use
this knowledge to develop diagnostic kits, treatments and vaccines for AMP
diseases.

    The TSX Venture Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of this release. This information
release may contain certain forward-looking information. Such information
involves known and unknown risks, uncertainties and other factors that may
cause actual results, performance or achievements to be materially different
from those implied by statements herein, and therefore these statements should
not be read as guarantees of future performance or results. All
forward-looking statements are based on the Company's current beliefs as well
as assumptions made by and information currently available to it as well as
other factors. Readers are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date of this press
release. Due to risks and uncertainties, including the risks and uncertainties
identified by the Company in its public securities filings, actual events may
differ materially from current expectations. The Company disclaims any
intention or obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise.





For further information:

For further information: Dr. George Adams, President & Chief Executive
Officer, Amorfix Life Sciences Ltd., Tel: (416) 482-3813, Fax: (416) 482-3811,
george.adams@amorfix.com; James Parsons, Chief Financial Officer, Amorfix Life
Sciences Ltd., Tel: (416) 482-3814, Fax: (416) 482-3811,
james.parsons@amorfix.com

Organization Profile

Amorfix Life Sciences Ltd.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890